Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Benzoyl peroxide/tretinoin - Sol-Gel Technologies

Drug Profile

Benzoyl peroxide/tretinoin - Sol-Gel Technologies

Alternative Names: Microencapsulated benzoyl peroxide 3% and microencapsulated tretinoin 0.1% cream; S6G5T 1/S6G5T 3; Tretinoin/benzoyl-peroxide; TWIN; Twyneo

Latest Information Update: 15 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sol-Gel Technologies
  • Class Anti-infectives; Antiacnes; Benzoic acids; Keratolytics; Oxidants; Retinoids; Skin disorder therapies; Small molecules
  • Mechanism of Action Protein synthesis inhibitors; Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Acne vulgaris

Most Recent Events

  • 06 Jun 2023 Searchlight Pharma in licenses Benzoyl peroxide/tretinoin from Sol-gel Technologies for commercialization in Canada
  • 27 Jan 2023 Benzoyl peroxide/tretinoin - Sol-Gel Technologies is available for licensing in World (excluding USA) as of 27 Jan 2023. https://www.sol-gel.com/
  • 25 Mar 2022 Launched for Acne vulgaris (In adolescents, In children, In the elderly, In adults) in USA - First global launch (Topical)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top